Health knowledge made personal
Join this community!
› Share page:
Search posts:

Aarkstore Enterprise Stemline Therapeutics, Inc. – Product Pipeline Review – Q2 2011

Posted Jul 15 2011 10:21am


Company’s pharmaceuticals report, “Stemline Therapeutics, Inc. - Product Pipeline Review - Q2 2011” provides data on the Stemline Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.  

This report is built using data and information sourced from Company’s proprietary databases, Stemline Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Stemline Therapeutics, Inc. and industry-specific third party sources, put together by Company’s team.  


- Stemline Therapeutics, Inc. - Brief Stemline Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Stemline Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Stemline Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.  
- Recent updates of the Stemline Therapeutics, Inc.’s pipeline in the last quarter.  
- Key discontinued and dormant projects.  
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Stemline Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.  
- Assess the growth potential of Stemline Therapeutics, Inc. in its therapy areas of focus.  
- Identify new drug targets and therapeutic classes in the Stemline Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.  
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.  
- Exploit collaboration and partnership opportunities with Stemline Therapeutics, Inc..  
- Avoid Intellectual Property Rights related issues.  
- Explore the dormant and discontinued projects of Stemline Therapeutics, Inc. and identify potential opportunities in those areas.

For more information please visit link:

Related Reports

Post a comment
Write a comment:

Related Searches